Sensus Healthcare anticipates significant revenue from FDA agreements in H2 2025
Q4 2024 Management View Joe Sardano, Chairman and CEO, highlighted the company’s strong business momentum in 2024, driven by record sales of SRT-100 systems and the expansion of the Fair Deal ...
Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
FiercePharma1d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
Founder and CEO of Karyon Bio, USA, highlights role of AI and Bioinformatics in healthcare
As the CEO of Karyon Bio, Thirunagari introduced the company’s ground breaking Digital Liver initiative, an AI-powered ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
FiercePharma6d
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...